Debt-to-equity of Inhibikase Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Inhibikase Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Inhibikase Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 8.3%, a 89% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Inhibikase Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 8.3% -65% -89% 30 Sep 2025
Q2 2025 10% -28% -74% 30 Jun 2025
Q1 2025 11% -15% -56% 31 Mar 2025
Q4 2024 16% -1.4% -8.4% 31 Dec 2024
Q3 2024 74% +58% +377% 30 Sep 2024
Q2 2024 38% +24% +165% 30 Jun 2024
Q1 2024 26% +11% +79% 31 Mar 2024
Q4 2023 17% +2.3% +16% 31 Dec 2023
Q3 2023 15% +2.6% +20% 30 Sep 2023
Q2 2023 14% +3.6% +33% 30 Jun 2023
Q1 2023 15% +6.4% +78% 31 Mar 2023
Q4 2022 15% +5.4% +58% 31 Dec 2022
Q3 2022 13% +0.2% +1.6% 30 Sep 2022
Q2 2022 11% 30 Jun 2022
Q1 2022 8.2% 31 Mar 2022
Q4 2021 9.3% 31 Dec 2021
Q3 2021 13% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.